HLZ
1-hydrazinophthalazine
Created: | 2010-03-02 |
Last modified: | 2021-03-13 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 20 |
Chiral Atom Count | 0 |
Bond Count | 21 |
Aromatic Bond Count | 11 |
Chemical Component Summary | |
---|---|
Name | 1-hydrazinophthalazine |
Synonyms | Hydralazine; phthalazin-1-ylhydrazine |
Systematic Name (OpenEye OEToolkits) | phthalazin-1-ylhydrazine |
Formula | C8 H8 N4 |
Molecular Weight | 160.176 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 12.01 | n2nc(c1ccccc1c2)NN |
SMILES | CACTVS | 3.370 | NNc1nncc2ccccc12 |
SMILES | OpenEye OEToolkits | 1.7.0 | c1ccc2c(c1)cnnc2NN |
Canonical SMILES | CACTVS | 3.370 | NNc1nncc2ccccc12 |
Canonical SMILES | OpenEye OEToolkits | 1.7.0 | c1ccc2c(c1)cnnc2NN |
InChI | InChI | 1.03 | InChI=1S/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12) |
InChIKey | InChI | 1.03 | RPTUSVTUFVMDQK-UHFFFAOYSA-N |
Drug Info: DrugBank
DrugBank ID | DB01275 |
---|---|
Name | Hydralazine |
Groups | approved |
Description | Originally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed.[A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.[T691] Hydralazine hydrochloride was FDA approved on 15 January 1953.[L8779] |
Synonyms |
|
Brand Names |
|
Indication | Hydralazine is indicated alone or adjunct to standard therapy to treat essential hypertension.[L8782] A combination product with isosorbide dinitrate is indicated as an adjunct therapy in the treatment of heart failure.[L8785] |
Categories |
|
ATC-Code |
|
CAS number | 86-54-4 |
Drug Targets
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Amine oxidase [copper-containing] 3 | MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQP... | unknown | inhibitor |
Hypoxia-inducible factor 1-alpha | MEGAGGANDKKKISSERRKEKSRDAARSRRSKESEVFYELAHQLPLPHNV... | unknown | inducer |
Prolyl 4-hydroxylase subunit alpha-1 | MIWYILIIGILLPQSLAHPGFFTSIGQMTDLIHTEKDLVTSLKDYIKAEE... | unknown | inhibitor |
Cytochrome P450 3A4 | MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI... | unknown | inhibitor |
Albumin | MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA... | unknown | binder |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
Resource Name | Reference |
---|---|
Pharos | CHEMBL276832 |
PubChem | 3637, 5538709, 5538708 |
ChEMBL | CHEMBL276832 |
ChEBI | CHEBI:5775 |
CCDC/CSD | HYDLAZ01, HYDLAZ10 |